دورية أكاديمية
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.
| العنوان: | Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. |
|---|---|
| المؤلفون: | Federico L; Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, USA., McGrail DJ; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Ravelli A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Karpinets T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Jiang P; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Reuben A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Negrao MV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Li J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Khairullah R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Weissferdt A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Vaporciyan AA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Antonoff MB; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Walsh G; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Lin SY; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Wistuba I; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Roth J; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Byers LA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Gaudreau PO; Department of Oncology, Queens' University and the Canadian Cancer Trials Group, Kingston, Canada., Uraoka N; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Cruz AF; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Dejima H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Lazcano RN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Solis LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Swisher S; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA., Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jzhang20@mdanderson.org., Sepesi B; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: bsepesi@mdanderson.org., Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: dlgibbon@mdanderson.org., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: cbernatchez@mdanderson.org. |
| المصدر: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Jan; Vol. 33 (1), pp. 42-56. Date of Electronic Publication: 2021 Oct 13. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : London : Elsevier Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990- |
| مواضيع طبية MeSH: | Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/pathology, CD8-Positive T-Lymphocytes ; Humans ; Lymphocytes, Tumor-Infiltrating/pathology ; Prognosis |
| مستخلص: | Background: Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been well established. Patients and Methods: Fresh tumor and normal adjacent tissue was prospectively collected from 150 patients with localized NSCLC. Tissue was comprehensively characterized by high-dimensional flow cytometry of TILs integrated with immunogenomic data from multiplex immunofluorescence, T-cell receptor sequencing, exome sequencing, RNA sequencing, targeted proteomics, and clinicopathologic features. Results: While neither the magnitude of TIL infiltration nor specific TIL subsets were significantly prognostic alone, the integration of high-dimensional flow cytometry data identified two major immunotypes (IM1 and IM2) that were predictive of recurrence-free survival independent of clinical characteristics. IM2 was associated with poor prognosis and characterized by the presence of proliferating TILs expressing cluster of differentiation 103, programmed cell death protein 1, T-cell immunoglobulin and mucin-domain containing protein 3, and inducible T-cell costimulator. Conversely, IM1 was associated with good prognosis and differentiated by an abundance of CD8 + T cells expressing cytolytic enzymes, CD4 + T cells lacking the expression of inhibitory receptors, and increased levels of B-cell infiltrates and tertiary lymphoid structures. While increased B-cell infiltration was associated with good prognosis, the best prognosis was observed in patients with tumors exhibiting high levels of both B cells and T cells. These findings were validated in patient tumors from The Cancer Genome Atlas. Conclusions: Our study suggests that although the number of infiltrating T cells is not associated with patient survival, the nature of the infiltrating T cells, resolved in distinct TIL immunotypes, is prognostically relevant in NSCLC and may inform therapeutic approaches to clinical care. Competing Interests: Disclosure CB has received research funding from Iovance Biotherapeutics and has participated in advisory committees for Myst Therapeutics and Turnstone Biologics. DLG has received research funding from AstraZeneca, Astellas, Janssen, Ribon Therapeutics, Takeda, and NGM Biopharmaceuticals, reports advisory role/consulting fees from AstraZeneca, Sanofi, Menarini Ricerche, and Eli Lilly, and research funding to MD Anderson Cancer Center from Boehringer Ingelheim. CH served on the advisory board for Briacell. SS has participated in advisory committees for Ethicon and for the Peter MacCallum Cancer Center. JVH has received research support from AstraZeneca, Bayer, GlaxoSmithKline, and Spectrum; participated in advisory committees for AstraZeneca, Boehringer Ingelheim, Exelixis, Genentech, GlaxoSmithKline, Guardant Health, Hengrui, Lilly, Novartis, Specrtum, EMD Serono, and Synta; and received royalties and/or licensing fees from Spectrum. TC has received speaker fees/honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche and Medscape Oncology, reports advisory role/consulting fees from MedImmune, AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals, and research funding to MD Anderson Cancer Center from Boehringer Ingelheim, MedImmune, AstraZeneca, Bristol Myers Squibb, and EMD Serono. JZ served on advisory board for AstraZeneca and Geneplus and received speaker’s fees from BMS, Geneplus, OrigMed, Innovent, grants from Merck, Johnson and Johnson from outside the submitted work. All other authors have declared no conflicts of interest. (Copyright © 2021. Published by Elsevier Ltd.) |
| التعليقات: | Comment in: Ann Oncol. 2022 Jan;33(1):4-5. (PMID: 34715315) |
| References: | Sci Rep. 2017 Oct 17;7(1):13380. (PMID: 29042640) NPJ Syst Biol Appl. 2017 Mar 6;3:8. (PMID: 28649435) Nat Rev Genet. 2014 Sep;15(9):585-98. (PMID: 24981601) Nat Cancer. 2020 May;1(5):546-561. (PMID: 32803172) Nat Immunol. 2017 Aug;18(8):940-950. (PMID: 28628092) Nat Commun. 2017 Feb 01;8:14381. (PMID: 28146145) Ann Oncol. 2015 Jan;26(1):64-70. (PMID: 25319062) Nat Commun. 2020 Jan 30;11(1):603. (PMID: 32001676) N Engl J Med. 2014 Dec 4;371(23):2189-2199. (PMID: 25409260) Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070) Science. 2015 Oct 9;350(6257):207-211. (PMID: 26359337) N Engl J Med. 2012 Jun 28;366(26):2455-65. (PMID: 22658128) Cancer Res. 2011 Jan 15;71(2):328-38. (PMID: 21224355) Mod Pathol. 2015 Sep;28(9):1154-66. (PMID: 26183759) Genome Res. 2018 Jan;28(1):66-74. (PMID: 29233924) Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075) Nature. 2020 Jan;577(7791):556-560. (PMID: 31942077) Expert Rev Anticancer Ther. 2016;16(1):13-20. (PMID: 26588948) J Immunol. 2002 May 1;168(9):4272-6. (PMID: 11970966) Immunotherapy. 2012 Mar;4(3):291-304. (PMID: 22401635) Nat Immunol. 2020 Nov;21(11):1346-1358. (PMID: 32868929) N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127) Nat Med. 2015 Aug;21(8):938-945. (PMID: 26193342) Expert Opin Biol Ther. 2016;16(3):397-406. (PMID: 26800463) Ann Oncol. 2016 Nov;27(11):2117-2123. (PMID: 27502728) CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402) Genome Med. 2017 Apr 19;9(1):34. (PMID: 28420421) JCI Insight. 2016 Sep 8;1(14):e89014. (PMID: 27699239) J Thorac Dis. 2018 Mar;10(3):1158-1161. (PMID: 29708136) Nat Genet. 2015 Dec;47(12):1402-7. (PMID: 26551669) J Clin Invest. 2014 May;124(5):2246-59. (PMID: 24667641) N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174) J Thorac Dis. 2013 Oct;5 Suppl 5:S463-78. (PMID: 24163740) J Immunother Cancer. 2019 May 17;7(1):129. (PMID: 31101066) Clin Cancer Res. 2018 Jan 15;24(2):407-419. (PMID: 29074606) Cell. 2017 May 4;169(4):750-765.e17. (PMID: 28475900) J Immunol. 2015 Apr 1;194(7):3475-86. (PMID: 25725111) Cell Rep. 2018 Apr 03;23(1):239-254.e6. (PMID: 29617664) Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517) Lancet Oncol. 2017 Aug;18(8):1009-1021. (PMID: 28694034) Nature. 2020 Jan;577(7791):561-565. (PMID: 31942071) Nat Med. 2018 Jul;24(7):994-1004. (PMID: 29892065) J Immunother Cancer. 2020 Apr;8(1):. (PMID: 32350118) Cancer Res. 2017 Dec 15;77(24):7072-7082. (PMID: 29021139) J Clin Invest. 2019 Nov 1;129(11):4992-5004. (PMID: 31609250) Immunity. 2013 Oct 17;39(4):782-95. (PMID: 24138885) N Engl J Med. 2019 Nov 21;381(21):2020-2031. (PMID: 31562796) Nature. 2011 Dec 21;480(7378):480-9. (PMID: 22193102) J Clin Oncol. 2010 Dec 20;28(36):5311-20. (PMID: 21079145) Oncoimmunology. 2017 Dec 18;7(2):e1378844. (PMID: 29416939) Cell. 2012 Sep 14;150(6):1107-20. (PMID: 22980975) Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592) CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787) N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407) Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44. (PMID: 24484236) Oncologist. 2016 May;21(5):643-50. (PMID: 27026676) Nature. 2019 Mar;567(7749):479-485. (PMID: 30894752) J Thorac Oncol. 2017 Jun;12(6):943-953. (PMID: 28341226) |
| معلومات مُعتمدة: | K99 CA240689 United States CA NCI NIH HHS; P30 CA016672 United States CA NCI NIH HHS; P50 CA070907 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: T cells; biomarkers; immune system; lung cancer; microenvironment |
| تواريخ الأحداث: | Date Created: 20211015 Date Completed: 20220303 Latest Revision: 20230317 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10019222 |
| DOI: | 10.1016/j.annonc.2021.09.021 |
| PMID: | 34653632 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1569-8041 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.09.021 |